| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basic Science Investigation |
1 CEA, DSV, I2BM, LIME, Orsay, France; 2 INSERM, U803, Orsay, France; 3 CREATIS-LRMN, CNRS, UMR 5220, and INSERM, U630, Bron, France; 4 Faculty of Life Sciences, AV Hill Building, University of Manchester, Manchester, United Kingdom; 5 Brain and Mind Research Institute, University of Sydney, Sydney, New South Wales, Australia; 6 Discipline of Medical Radiation Sciences, University of Sydney, Sydney, New South Wales, Australia; and 7 School of Chemistry, University of Sydney, Sydney, New South Wales, Australia
Correspondence: For correspondence or reprints contact: Bertrand Tavitian, INSERM U803, CEA, LIME, 4 place du général Leclerc, F-91401 Orsay, France. E-mail: bertrand.tavitian{at}cea.fr
Overexpression of the translocator protein, TSPO (18 kDa), formerly known as the peripheral benzodiazepine receptor, is a hallmark of activation of cells of monocytic lineage (microglia and macrophages) during neuroinflammation. Radiolabeling of TSPO ligands enables the detection of neuroinflammatory lesions by PET. Two new radioligands, 11C-labeled N,N-diethyl-2-[2-(4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-
]pyrimidin-3-yl]acetamide (DPA-713) and 18F-labeled N,N-diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo[1,5-]pyrimidin-3-yl)acetamide (DPA-714), both belonging to the pyrazolopyrimidine class, were compared in vivo and in vitro using a rodent model of neuroinflammation. Methods: 11C-DPA-713 and 18F-DPA-714, as well as the classic radioligand 11C-labeled (R)-N-methyl-N-(1-methylpropyl)-1-(2-chlorophenyl)isoquinoline-3-carboxamide (PK11195), were used in the same rat model, in which intrastriatal injection of (R,S)--amino-3-hydroxy-5-methyl-4-isoxazolopropionique gave rise to a strong neuroinflammatory response. Comparative endpoints included in vitro autoradiography and in vivo imaging on a dedicated small-animal PET scanner under identical conditions. Results: 11C-DPA-713 and 18F-DPA-714 could specifically localize the neuroinflammatory site with a similar signal-to-noise ratio in vitro. In vivo, 18F-DPA-714 performed better than 11C-DPA-713 and 11C-PK11195, with the highest ratio of ipsilateral to contralateral uptake and the highest binding potential. Conclusion: 18F-DPA-714 appears to be an attractive alternative to 11C-PK11195 because of its increased bioavailability in brain tissue and its reduced nonspecific binding. Moreover, its labeling with 18F, the preferred PET isotope for radiopharmaceutical chemistry, favors its dissemination and wide clinical use. 18F-DPA-714 will be further evaluated in longitudinal studies of neuroinflammatory conditions such as are encountered in stroke or neurodegenerative diseases.
Key Words: TSPO (18-kDa) • PBR • peripheral benzodiazepine receptor • PET • neuroinflammation • 18F-DPA-714 • 11C-DPA-713 • 11C-PK11195
COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.
Related articles in JNM:
This article has been cited by other articles:
|
|
 |
|
  A. Winkeler, R. Boisgard, A. Martin, and B. Tavitian Radioisotopic Imaging of Neuroinflammation J. Nucl. Med., January 1, 2010; 51(1): 1 - 4. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Fujimura, Y. Kimura, F. G. Simeon, L. P. Dickstein, V. W. Pike, R. B. Innis, and M. Fujita Biodistribution and Radiation Dosimetry in Humans of a New PET Ligand, 18F-PBR06, to Image Translocator Protein (18 kDa) J. Nucl. Med., January 1, 2010; 51(1): 145 - 149. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
